Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2009

13 - Primary central nervous system lymphoma

Summary

Introduction

Primary central nervous system lymphoma (PCNSL) is a relatively rare non-Hodgkin's lymphoma that arises within the CNS. Until recently, it accounted for only 1% of all primary brain tumors, but its incidence increased threefold in immunocompetent populations from 1988 to the time of writing (Eby et al., 1988). With a median age at diagnosis of 60 years (Peterson & DeAngelis, 1997), PCNSL is a disease of middle and late adult life, and it is slightly more common in males (O'Neill & Illig, 1989). It is an infiltrative tumor most often located in the periventricular region and subcortical gray matter (Grant & Isaacson, 1992) (Figure 13.1). Leptomeningeal involvement is present in approximately one-third of patients at diagnosis (Peterson & DeAngelis, 1997), and the eye is another site of multifocal CNS involvement in about 25% of patients (Peterson et al., 1993). On neuroimaging studies, PCNSL is identified as contrast-enhancing in 90% of cases, and multifocal lesions occur in approximately 40% of patients (DeAngelis, 1995).

Diagnosis and treatment

Patients may present with focal neurological signs, such as weakness, gait disturbance, language dysfunction, or seizures. Generalized symptoms of increased intracranial pressure, headache, or progressive cognitive decline may also occur at presentation. The diagnosis of PCNSL involves stereotactic brain biopsy or demonstration of malignant lymphocytes in the cerebrospinal fluid (CSF) or vitreous in cases of ocular involvement. Surgical resection is often not beneficial, and the deep-seated nature of most lesions increases the risk of possible surgical complications (DeAngelis et al., 1990).

REFERENCES
Abrey, , DeAngelis, LM, Yahalom, J (1998). Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859–863.
Abrey, , Yahalom, J, DeAngelis, LM (2000). Treatment of primary CNS lymphoma: the next step. J Clin Oncol 18: 3144–3150.
Abrey, L, Moskowitz, CH, Mason, WPet al. (2003). Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21: 4151–4156.
Batchelor, T, Loeffler, JS (2006). Primary CNS lymphoma. J Clin Oncol 24: 1281–1288.
Behin, A, Delattre, J-Y (2003). Neurologic sequelae of radiotherapy on the nervous system. In Schiff, D, Wen, PY (eds.) Cancer Neurology in Clinical Practice (pp. 173–191). Totowa, NJ: Humana Press Inc.
Besell, EM, Graus, F, Lopez-Guillermo, Aet al. (2001). CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 50: 457–464.
Blay, J-Y, Conroy, T, Chevreau, Cet al. (1998). High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864–871.
Boiardi, A, Silvani, A, Valentini, Set al. (1993). Chemotherapy as a first treatment for primary non-Hodgkin's lymphoma of the central nervous system: preliminary data. J Neurol 241: 96–100.
Cher, L, Glass, J, Harsh, GRet al. (1996). Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred chemotherapy: preliminary results. Neurology 46: 1757–1759.
Constine, LS, Konski, A, Ekholm, Set al. (1988). Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 15: 319–330.
Correa, DD, Anderson, ND, Glass, Aet al. (2003). Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol 1: 490.
Correa, DD, DeAngelis, LM, Shi, Wet al. (2004). Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62: 548–555.
Corry, J, Smith, JG, Wirth, Aet al. (1998). Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol 41: 615–620.
Crossen, JR, Goldman, DL, Dahlborg, SAet al. (1992). Neuropsychological asssessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 30: 23–29.
Dahlborg, SA, Henner, WD, Crossen, JRet al. (1996). Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166–174.
Dahlborg, SA, Petrillo, A, Crossen, JRet al. (1998). The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4(2): 110–124.
DeAngelis, LM (1995). Current management of primary central nervous system lymphoma. Oncology 9: 63–71.
DeAngelis, LM, Hormigo, A (2004). Treatment of primary central nervous system lymphoma. Semin Oncol 31: 684–692.
DeAngelis, LM, Shapiro, WR (1991). Drug/radiation interactions and central nervous system injury. In Gutin, PH, Leibel, SA, Sheline, GE (eds.) Radiation Injury to the Nervous System (pp. 361–382). New York: Raven Press.
DeAngelis, LM, Delattre, J-Y, Posner, JB (1989). Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796.
DeAngelis, LM, Yahalom, J, Heinemann, MH, Cirrincione, C, Thaler, HT, Krol, G (1990). Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40(1): 80–86.
DeAngelis, LM, Yahalom, J, Thaler, HTet al. (1992). Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635–643.
Desmond, DW (2002). Cognition and white matter lesions. Cerebrovasc Dis 13: 53–57.
Doolittle, ND, Miner, ME, Siegal, Tet al. (2000). Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637–647.
Dropcho, EJ (1991). Central nervous system injury by therapeutic irradiation. Neurol Clin 9: 69–88.
Eby, NL, Grufferman, S, Flannelly, CMet al. (1988). Increasing incidence of primary brain lymphoma in the U.S. Cancer 62: 2461–2465.
Ferreri, AJM, Reni, M, Pasini, Fet al. (2002). A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513–1520.
Fliessbach, K, Urbach, H, Helmstaedter, Cet al. (2003). Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60: 563–568.
Fliessbach, K, Helmstaedter, C, Urbach, Het al. (2005). Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64: 1184–1188.
Freilich, RJ, Delattre, J-Y, Monjour, A, DeAngelis, LM(1996). Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435–439.
Glass, J, Gruber, ML, Cher, L, Hochberg, F (1994). Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 88–195.
Grant, JW, Isaacson, PG (1992). Primary central nervous system lymphoma. Brain Pathol 2: 97–109.
Guha-Thakurta, N, Damek, D, Pollack, Cet al. (1999). Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259–268.
Harder, H, Holtel, H, Bromberg, JECet al. (2004). Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62: 544–547.
Herrlinger, U, Schabet, M, Clemens, Met al. (1998). Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 97: 257–264.
Herrlinger, U, Schabet, M, Brugger, Wet al. (2002). German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247–252.
Herrlinger, U, Kuker, W, Uhl, Met al. (2005). NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57: 843–847.
Hoang-Xuan, K, Taillandier, L, Chinot, Oet al. (2003). Chemotherapy alone as initial treatment for CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Control Group. J Clin Oncol 21: 2726–2731.
Keime-Guibert, F, Napolitano, M, Delattre, JY (1998). Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708.
Kraemer, DF, Fortin, D, Neuwelt, EA (2002). Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Curr Neurol Neurosci Rep 2: 216–224.
Laack, NN, Brown, PD (2004). Cognitive sequelae of brain radiation in adults. Semin Oncol 31: 702–713.
Lai, R, Abrey, , Rosenblum, MK, DeAngelis, LD (2004). Treatment-induced leukoencephalopathy in primary CNS lymphoma. Neurology 62: 451–456.
McAllister, LD, Doolittle, ND, Guastadisegni, PEet al. (2000). Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46: 51–61.
Meyers, CA, Wefel, JS (2003). The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21: 3557–3558.
Nelson, DF (1999). Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 43: 241–247.
Neuwelt, EA, Goldamn, DA, Dahlborg, SAet al. (1991). Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580–1590.
Neuwelt, EA, Guastadisegni, PE, Varallyay, Pet al. (2005). Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 26: 258–265.
O'Brien, P, Roos, D, Pratt, Get al. (2000). Phase II multicenter study of a brief single agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519–526.
O'Neill, BP (2004). Neurocognitive outcomes in primary CNS lymphoma (PCNSL). Neurology 62: 532–533.
O'Neill, BP, Illig, JJ (1989). Primary central nervous system lymphoma. Mayo Clinic Proc 64: 1005–1020.
Pels, H, Schlegel, U (2006). Primary central nervous system lymphoma. Curr Treat Options Neurol 8: 346–357.
Pels, H, Deckert-Schulter, M, Glasmacher, Aet al. (2000). Primary central nervous system lymphoma: a clinicopathological study of 28 cases. Hematol Oncol 18: 21–32.
Pels, H, Schmidt-Wolf, IGH, Glasmacher, Aet al. (2003). Primary central nervous system lymphoma: results of a pilot study and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489–4495.
Peterson, K, DeAngelis, LM (1997). Primary cerebral lymphoma. In Vecht, CJ (ed.) Handbook of Clinical Neurology (Vol. 24, pp. 257–268). Part II: Neuro-Oncology. Amsterdam: Elsevier Science.
Peterson, K, Gordon, KB, Heinemann, M-Het al. (1993). The clinical spectrum of ocular lymphoma. Cancer 72: 843–849.
Poortmans, PMP, Kluin-Nelemans, HC, Haaxma-Reiche, Het al. (2003). High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II Trial 20962. J Clin Oncol 21: 4483–4488.
Roman-Goldstein, SM, Mitchell, P, Crossen, JRet al. (1995). MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Am J Neuroradiol 16: 543–553.
Sandor, V, Stark-Vancs, V, Pearson, Det al. (1998). Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000–3006.
Sarazin, M, Ameri, A, Monjour, Aet al. (1995). Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur J Cancer 31A: 2003–2007.
Schlegel, U, Pels, H, Glasmacher, Aet al. (2001). Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 71: 118–122.
Sheline, G (1980). Irradiation injury of the human brain: a review of clinical experience. In Gilbert, HA, Kagan, AR (eds.) Radiation Damage to the Nervous System (pp. 39–68). New York: Raven Press.
Sheline, G, Wara, WM, Smith, V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Physics 6: 1215–1228.
Tofilon, PJ, Fike, JR (2000). The radioresponse of the central nervous system: a dynamic process. Radiat Res 153: 357–370.
Tullberg, M, Fletcher, E, DeCarli, Cet al. (2004). White matter lesions impair frontal lobe function regardless of their location. Neurology 63: 246–253.
Maazen, RW, Kleiboer, BJ, Verhagen, Iet al. (1993). Repair capacity of adult rat glial progenitor cells determined by an in vitro clonogenic assay after in vitro or in vivo fractionated irradiation. Int J Radiat Biol 63: 661–666.
Weitzner, MA, Meyers, CA (1997). Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 6: 169–177.